Keywords: Contrast Agents, Contrast Agents, Cancer, Novel Contrast Mechanisms
Motivation: Patients with contraindications to gadolinium-based contrast agents (GBCAs), such as those with renal impairment, require alternative imaging options that ensure safety without compromising diagnostic quality.
Goal(s): This study aimed to demonstrate the superiority of ferumoxytol (FER)-enhanced MRI over pre-contrast imaging in assessing malignant brain lesions, focusing on improving lesion visualization.
Approach: This study was conducted by an independent clinical research organization and adhered to FDA guidelines. Three neuroradiologists evaluated FER-enhanced MRI images against pre-contrast scans in 153 patients with primary or metastatic brain tumors.
Results: FER-enhanced MRI demonstrated significant improvement in lesion visualization compared to pre-contrast imaging.
Impact: The results from this study provide strong evidence that ferumoxytol could serve as a safe and effective alternative to gadolinium-based contrast agents, particularly for patients with contraindications, potentially leading to its FDA approval for brain tumor imaging.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords